<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537055</url>
  </required_header>
  <id_info>
    <org_study_id>201110021MD</org_study_id>
    <nct_id>NCT01537055</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy</brief_title>
  <official_title>Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and tolerability of levofloxacin-based sequential therapy and triple
      therapy in the second line therapy for those who fail from one eradication therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 600 patients who failed from first line triple therapy or sequential therapy will be
      eligible in this multicenter randomized comparative trial. Eligible patients will be
      randomized to receive either (1) levofloxacin-based sequential therapy for 10
      days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole
      30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice
      daily)〕or (2) levofloxacin-based triple therapy for 10 days〔lansoprazole 30mg and amoxicillin
      1g, and levofloxacin 250mg for 10 days (all given twice daily)〕. Eradication will be
      confirmed with 13C-Urea Breath Test 6 weeks after therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate in the second line therapy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by UBT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effect</measure>
    <time_frame>2 weeks</time_frame>
    <description>during treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Eradication Rate for Helicobacter</condition>
  <arm_group>
    <arm_group_label>levofloxacin-based sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levofloxacin-based sequential therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levofloxacin-based triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levofloxacin-based triple therapy for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin-based sequential therapy</intervention_name>
    <description>levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕</description>
    <arm_group_label>levofloxacin-based sequential therapy</arm_group_label>
    <other_name>Takepron</other_name>
    <other_name>Cravit</other_name>
    <other_name>Flagyl</other_name>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin-based triple therapy for 10 days</intervention_name>
    <description>lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)</description>
    <arm_group_label>levofloxacin-based triple therapy</arm_group_label>
    <other_name>Takepron</other_name>
    <other_name>Cravit</other_name>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  H. pylori infected patients who failed from first line therapy will be eligible in
             this study

        Exclusion Criteria:

          -  Patients were excluded from the study if any one of the following criteria was
             present:

          -  children and teenagers aged less than 20 years,

          -  history of gastrectomy,

          -  gastric malignancy, including adenocarcinoma and lymphoma,

          -  previous allergic reaction to antibiotics (amoxicillin, metronidazole, levofloxacin)
             and PPI (lansoprazole),

          -  contraindication to treatment drugs,

          -  pregnant or lactating women, or

          -  severe concurrent disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Ming Liou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD</last_name>
    <phone>886-972651883</phone>
    <email>dtmed046@pchome.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Hsinchu Branch</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Fong Hsu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>E-DA Hospital and I-Shou University</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-yang Chang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeng-Yih Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Bureau of Lienchiang County</name>
      <address>
        <city>Lienchiang</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng-Yun Tsao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Ming Liou, MD</last_name>
      <phone>886-972651883</phone>
      <email>dtmed046@pchome.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Hsiung Chang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Chao Chang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing-Chuan Luo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taitung Branch</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Jong Bair</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital , Yunlin</name>
      <address>
        <city>Yunlin</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh-Chang Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2011 Aug;66(8):1847-52. doi: 10.1093/jac/dkr217. Epub 2011 May 31.</citation>
    <PMID>21632579</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <last_update_submitted>January 30, 2015</last_update_submitted>
  <last_update_submitted_qc>January 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Taiwan University Hospital</investigator_affiliation>
    <investigator_full_name>National Taiwan University Hospital</investigator_full_name>
    <investigator_title>National Taiwan University Hospital</investigator_title>
  </responsible_party>
  <keyword>H pylori eradication</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

